Literature DB >> 20629652

Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage.

H Zhu1, H-P Wang, Y Jiang, S-P Hou, Y-J Liu, Q-Z Liu.   

Abstract

Thirteen strains of Chlamydia trachomatis were exposed to subinhibitory concentrations of erythromycin (0.5 microg ml(-1)), azithromycin (0.5 microg ml(-1)) and josamycin (0.04 microg ml(-1)) to select macrolide-resistant mutants with serial passages. The C. trachomatis mutants presented with low-level resistance to erythromycin, azithromycin and josamycin for which a 16-fold increase, a 16-fold increase and an 8-fold increase respectively in the minimal inhibitory concentration (MICs) for the mutant strains compared with the MIC for the susceptible strains were found. The results of chemosensitivity showed that josamycin had the highest susceptibility rate compared with erythromycin and azithromycin in the treatment of C. trachomatis. The ribosomal protein L4 and 23S rRNA genes of the susceptible and resistant strains of C. trachomatis were partially sequenced. A double mutation was found in ribosomal protein L4 of the mutants, leading to Pro109(CCG)-->Leu(CTG), and Pro151(CCG)-->Ala(GCC) (Escherichia coli numbering) in the corresponding protein, but these mutations were also found in parent strains. An investigation into the sequences of 23S rRNAs in the mutants revealed point mutations of A2057G, A2059G and T2611C (E. coli numbering). These results suggest that point mutations located in 23S rRNA were associated with macrolide resistance in C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20629652     DOI: 10.1111/j.1439-0272.2009.01019.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  6 in total

1.  A cohort study of Chlamydia trachomatis treatment failure in women: a study protocol.

Authors:  Jane S Hocking; Lenka A Vodstrcil; Wilhelmina M Huston; Peter Timms; Marcus Y Chen; Karen Worthington; Ruthy McIver; Sepehr N Tabrizi
Journal:  BMC Infect Dis       Date:  2013-08-17       Impact factor: 3.090

2.  Whole-genome enrichment and sequencing of Chlamydia trachomatis directly from clinical samples.

Authors:  Mette T Christiansen; Amanda C Brown; Samit Kundu; Helena J Tutill; Rachel Williams; Julianne R Brown; Jolyon Holdstock; Martin J Holland; Simon Stevenson; Jayshree Dave; C Y William Tong; Katja Einer-Jensen; Daniel P Depledge; Judith Breuer
Journal:  BMC Infect Dis       Date:  2014-11-12       Impact factor: 3.090

3.  Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS/MS).

Authors:  Lenka A Vodstrcil; Thusitha W T Rupasinghe; Fabian Y S Kong; Dedreia Tull; Karen Worthington; Marcus Y Chen; Wilhelmina M Huston; Peter Timms; Malcolm J McConville; Christopher K Fairley; Catriona S Bradshaw; Sepehr N Tabrizi; Jane S Hocking
Journal:  PLoS One       Date:  2017-05-12       Impact factor: 3.240

4.  Chlamydial clinical isolates show subtle differences in persistence phenotypes and growth in vitro.

Authors:  Mark Thomas; Amba Lawrence; Samuel Kroon; Lenka A Vodstrcil; Samuel Phillips; Jane S Hocking; Peter Timms; Wilhelmina M Huston
Journal:  Access Microbiol       Date:  2021-02-19

Review 5.  Treatment challenges for urogenital and anorectal Chlamydia trachomatis.

Authors:  Fabian Yuh Shiong Kong; Jane Simone Hocking
Journal:  BMC Infect Dis       Date:  2015-07-29       Impact factor: 3.090

Review 6.  An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.

Authors:  Ahmed Moussa; Fouzia Radouani; Ichrak Benamri; Maryame Azzouzi; Kholoud Sanak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-09-03       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.